EB research firms make the news as they make progress in funding or approvals for their trials. Here are some of those articles:
- The Worst Disease You’ve Never Heard Of and Why It Matters July 2016
- The Butterfly Effect
- Recessive Dystrophic Epidermolysis Bullosa: Advances in the Laboratory Leading to New Therapies
- FDA grants rare pediatric disease status to FCX-007 for recessive dystrophic epidermolysis bullosa
- Fibrocell Receives Rare Pediatric Disease Designation From FDA for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) May 12, 2015
- Case report: rapidly healing epidermolysis bullosa wound after ablative fractional resurfacing. Jan 2, 2015
- Scioderm to Present at 33rd Annual J.P. Morgan Healthcare Conference, Jan 2, 2015
- Durham’s Scioderm raises $20M to treat rare disease that targets infants and children. Dec 18, 2014
- Shire shares intravenous protein replacement therapy for dystrophic EB in a presentation. Dec 10, 2014
- Blistering skin disease may be treatable with ‘therapeutic reprogramming,’ researchers say. Nov 26, 2014
- Stem cells show potential for treating rare skin disease. Nov 26, 2014
- Pearl Jam frontman, Microsoft raise money for EB research. Nov 13, 2014
